Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05470387
Other study ID # PBI-POI-301
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date June 28, 2022
Est. completion date August 11, 2023

Study information

Verified date April 2024
Source Palisade Bio
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of LB1148 in subjects undergoing planned bowel resection.


Description:

This will be a multicenter, randomized, double-blind, placebo-controlled, study to evaluate the safety and efficacy of LB1148 in return to bowel function for subjects undergoing planned bowel resection.


Recruitment information / eligibility

Status Terminated
Enrollment 23
Est. completion date August 11, 2023
Est. primary completion date March 6, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: Subjects will be eligible for participation in the study only if they meet ALL of the following inclusion criteria: 1. Adults age 18 to 80 years, inclusive. 2. Scheduled to undergo a planned (non-emergent) bowel resection via minimally invasive technique or laparotomy. This includes any subject in which a resection of the small intestine, colon, or rectum is performed for any elective indication. 3. Willing to perform and comply with all study procedures including, being hospitalized until achieving GI-2 and responding to telephone follow-up visits as scheduled. 4. Willing and able to provide written informed consent. Exclusion Criteria: Subjects will not be eligible for participation in the study if they meet ANY of the following exclusion criteria: 1. History of total colectomy. 2. Has a preexisting ostomy. 3. History of radiation enteritis. 4. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2. 5. History of seizure disorder. 6. History of myeloproliferative disorders. 7. American Society of Anesthesiologists (ASA) Class IV or V. 8. Inability to take IP orally or consume solid food. 9. Planned treatment with alvimopan (EnteregĀ®) during hospitalization period 10. Chronic opioid usage, defined by the American Pain Society as daily or near-daily use of opioids for at least 90 days. 11. Men and women of child bearing potential (WOCBP) who are unwilling to practice a highly effective method of contraception that may include, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with vasectomized partner, vasectomy, hysterectomy, bilateral tubal ligation, licensed hormonal methods (but not combination hormonal methods), intrauterine device, or use of spermicide combined with a barrier method (e.g., condom, diaphragm) for 28 days before Day 1 and through Day 30. 12. Women who will not agree to stop combined hormonal contraceptive and or combined hormonal replacement therapy (including combined hormonal pill, patch or vaginal ring) during the 7 day period prior to Surgery (Study Day 2) through the 7 day period following surgery (Study Days 3 through 9). 13. Has contraindications or potential risk factors to taking TXA. These include subjects with: - Known sensitivity to TXA - Recent craniotomy (past 30 days) - Active cerebrovascular bleed - Active thromboembolic disease (such as deep vein thrombosis, pulmonary embolism, cerebral thrombosis, ischemic stroke, or acute coronary syndrome) - Acute promyelocytic leukemia taking all-trans retinoic acid for remission induction 14. Receipt of any investigational drug within 28 days or 5 half-lives prior to Day 1. 15. Any other condition that, in the opinion of the Investigator would make the subject unsuitable for the study or unable to comply with the study requirements.

Study Design


Intervention

Drug:
LB1148
A total of 700 mL of drug product will be administered orally as a split dose before surgery.
Placebo
A total of 700 mL of placebo will be administered orally as a split dose before surgery.

Locations

Country Name City State
United States Site 321 Baltimore Maryland
United States Site 359 Bridgeport Connecticut
United States Site 324 Burlington Massachusetts
United States Site 318 Chapel Hill North Carolina
United States Site 351 Clearwater Florida
United States Site 313 Columbus Ohio
United States Site 320 Dallas Texas
United States Site 355 Grand Rapids Michigan
United States Site 319 Houston Texas
United States Site 357 Iowa City Iowa
United States Site 358 Jacksonville Florida
United States Site 354 La Jolla California
United States Site 331 Miami Florida
United States Site 315 Mobile Alabama
United States Site 317 New York New York
United States Site 356 New York New York
United States Site 329 Orange California
United States Site 353 Providence Rhode Island
United States Site 325 Rochester Minnesota
United States Site 352 Saint Louis Missouri
United States Site 326 Salt Lake City Utah
United States Site 350 San Diego California
United States Site 312 Torrance California

Sponsors (1)

Lead Sponsor Collaborator
Palisade Bio

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to Return of Gastrointestinal Function The later of the times in hours from placement of the last skin staple or suture to the time of toleration of solid food (defined as the time a subject finished a meal that required chewing and experienced no significant nausea/vomiting for 4 hours after the solid meal) and the first bowel movement, up to 14 days post-surgery From surgical procedure up to 14 days in hospital
Secondary Time to First Bowel Movement Time in hours from placement of the last skin staple or suture to the time of first bowel movement From surgical procedure up to 14 days in hospital
Secondary Time Subject is Ready for Discharge Time subject is ready for discharge, defined as the time from the end of surgery to the time the subject is ready for hospital discharge solely based on the recovery of GI function, as determined by the surgeon From surgical procedure up to 14 days in hospital
Secondary Time Discharge Order Written Time discharge order written, defined as the time from the end of surgery to the time that the hospital discharge order is written From surgical procedure up to 14 days in hospital
Secondary Time of Actual Discharge Time of actual discharge, defined as the time from the end of surgery to the time the subject is actually discharged from the hospital From surgical procedure up to 14 days in hospital
See also
  Status Clinical Trial Phase
Terminated NCT00065234 - Acupuncture to Prevent Postoperative Bowel Paralysis (Paralytic Ileus) Phase 2
Completed NCT01156129 - Interventions to Decrease the Impact of Post-OPerative Ileus After Liver Transplant or Resection Surgery Phase 1
Recruiting NCT05712525 - Gut Recovery In Patients Following Surgery
Completed NCT06338813 - Digital Manometry for Intra-Abdominal Pressure Measurement in Ileus N/A
Recruiting NCT05315765 - Development of a Patient Reported Outcome Measure for GastroIntestinal Recovery
Completed NCT02161367 - Effect of Simethicone on Postoperative Ileus in Patients Undergoing Colorectal Surgery Phase 4
Completed NCT03711487 - The Effect of Foeniculum Vulgare Ironing on Gastrointestinal Recovery After Colorectal Resection Phase 2
Completed NCT00528970 - A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair Phase 3
Not yet recruiting NCT04001985 - Nasogastric Tube Clamping Trial vs. Immediate Removal N/A
Completed NCT02836470 - A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection Phase 2
Completed NCT04100447 - A Study to Evaluate the Safety, Tolerability and Efficacy of LB1148 for Subjects Undergoing Elective Bowel Resection Phase 1
Active, not recruiting NCT03795467 - Peripheral Perfusion Index, Haemoglobin and Blood Transfusion in Acute Surgical Patients
Completed NCT01143259 - Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use N/A
Terminated NCT03352414 - Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC Phase 2
Not yet recruiting NCT04305730 - Use of Pedometer Following Radical Cystectomy N/A
Completed NCT02760290 - Comparison of Extraperitoneal and Intraperitoneal Cesarean Technique N/A
Active, not recruiting NCT02399605 - Subcutaneous Electrical Stimulation in the Prevention of Postoperative Ileus N/A
Completed NCT00388258 - Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus Phase 3
Completed NCT00205842 - Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus Phase 3
Enrolling by invitation NCT05298774 - Myoelectric Activity Following Colorectal Surgery and Return of Bowel Function N/A